Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AB Science S.A. AB.PA
$4.80
-$0.1 (-2.14%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
250949620.00000000
-
week52high
11.10
-
week52low
4.64
-
Revenue
958000
-
P/E TTM
-19
-
Beta
0.78549600
-
EPS
-0.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
28 апр 2023 г. в 16:41
Описание компании
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии